Press Releases AnGes, Inc.

Equities

4563

JP3127700007

Market Closed - Japan Exchange Other stock markets 07:00:00 10/05/2024 BST			5-day change	1st Jan Change
49 ^JPY	-2.00%		0.00%	-31.94%

01-19	Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	MT
01-18	Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AnGes : Consolidated Financial Report for the First Quarter 2024	05-10	PU
AnGes : Notice Regarding the Decision to Sell the ZOKINVY Business of Eiger BioPharmaceuticals, Inc.	05-08	PU
AnGes : Notice on the NHI Drug Price Standard Listing and Launch Schedule of Zokinvy for the Treatment of Progeria	04-17	PU
AnGes : Notice Regarding Eiger BioPharmaceuticals, Inc.	04-12	PU
AnGes : Notice of Business Restructuring at Consolidated Subsidiary	03-15	PU
AnGes : Notice of Conclusion of License Agreement and Revision of Consolidated Financial Results Forecast for FY2024	03-14	PU
Eiger and Partner, AnGes, Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	01-19	AQ
AnGes : Consolidated Financial Report for the Third Quater 2023	11-07	PU
AnGes : Notice Regarding the Start of Administration of NF-κB Decoy Oligo DNA for the Treatment of Chronic Intervertebral Disc Lumbago in a Phase II Clinical Trial in Japan	18/10/23	PU
AnGes : Consolidated Financial Report Q2 2023	09/08/23	PU
AnGes : Consolidated Financial Report for the Second Quater 2023	09/08/23	PU
AnGes : Clinical Research Laboratory has now established "Genetic Testing" technology and aims to begin accepting orders for "genetic testing" in winter 2023	24/07/23	PU
AnGes : Begin contracted expanded newborn screening from municipalities and related institutions from April 2024 at AnGes Clinical Research Laboratory	18/07/23	PU
AnGes : Begin contracted expanded newborn screening from municipalities and related institutions from April 2024 on AnGes Clinical Research Laboratory	18/07/23	PU
AnGes : filed for approval of its HGF gene therapy product Collategene® for the first time since the introduction of the conditional/time-limited authorization system for regenerative medicine products	31/05/23	PU
AnGes : Notice on the Filing of an Application for Manufacturing and Marketing Approval of Zokinvy for the Treatment of Premature Aging Syndrome	12/05/23	PU
AnGes : Consolidated Financial Report for the First Quater 2023	10/05/23	PU
AnGes : Notice Concerning Acquisition and Cancellation of the 42nd Series of Stock Acquisition Rights	24/04/23	PU
Notice of Orphan Drug Designation for lonafarnib (U.S. brand name: Zokinvy) for the treatment of premature aging (HGPS and PL)	28/03/23	PU
AnGes : Notice of Completion of Patient Enrollment in Late Phase II Clinical Trial of HGF Gene Therapy Product "Collategene" in the U.S.	09/03/23	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AnGes, Inc.

Equities

4563

JP3127700007

Press Releases

Filters